Literature DB >> 17934713

Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study.

A Jeandrot1, J-L Richard, C Combescure, N Jourdan, S Finge, M Rodier, P Corbeau, A Sotto, J-P Lavigne.   

Abstract

AIMS/HYPOTHESIS: Infection of diabetic foot ulcers is common; at early stages it is difficult to differentiate between non-infected ulcers (or those colonised with normal flora) and ulcers infected with virulent bacteria that lead to deterioration. This pilot study aimed to assess the diagnostic accuracy of inflammatory markers as an aid to making this distinction.
METHODS: We included 93 diabetic patients who had an episode of foot ulcer and had not received antibiotics during the 6 months preceding the study. Ulcers were classified as infected or uninfected, according to the Infectious Diseases Society of America-International Working Group on the Diabetic Foot classification. Diabetic patients without ulcers (n=102) served as controls. C-reactive protein (CRP), orosomucoid, haptoglobin and procalcitonin were measured together with white blood cell and neutrophil counts. The diagnostic performance of each marker, in combination (using logistic regression) or alone, was assessed.
RESULTS: As a single marker, CRP was the most informative for differentiating grade 1 from grade 2 ulcers (sensitivity 0.727, specificity 1.000, positive predictive value 1.000, negative predictive value 0.793) with an optimal cut-off value of 17 mg/l. In contrast, white blood cell and neutrophil counts were not predictive. The most relevant combination derived from the logistic regression was the association of CRP and procalcitonin (AUC 0.947), which resulted in a significantly more effective determination of ulcer grades, as shown by comparing receiver operating characteristic curves. CONCLUSIONS/
INTERPRETATION: Measurement of only two inflammatory markers, CRP and procalcitonin, might be of value for distinguishing between infected and non-infected foot ulcers in subgroups of diabetic patients, to help ensure the appropriate allocation of antibiotic treatment. Nevertheless, external validation of the diagnostic value of procalcitonin and CRP in diabetic foot ulcers is needed before routine use can be recommended.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934713      PMCID: PMC4749667          DOI: 10.1007/s00125-007-0840-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  25 in total

Review 1.  Wound microbiology and associated approaches to wound management.

Authors:  P G Bowler; B I Duerden; D G Armstrong
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 2.  Infection in chronic wounds: controversies in diagnosis and treatment.

Authors:  G Dow; A Browne; R G Sibbald
Journal:  Ostomy Wound Manage       Date:  1999-08       Impact factor: 2.629

3.  Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation.

Authors:  S Hammer; F Meisner; P Dirschedl; G Höbel; P Fraunberger; B Meiser; B Reichardt; C Hammer
Journal:  Transpl Immunol       Date:  1998-12       Impact factor: 1.708

4.  Reliability of semiquantitative determination of procalcitonin serum concentrations in neonates.

Authors:  Agnieszka Kordek; Wojciech Podraza; Ryszard Czajka
Journal:  Diagn Microbiol Infect Dis       Date:  2006-07-21       Impact factor: 2.803

5.  Probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?

Authors:  Lawrence A Lavery; David G Armstrong; Edgar J G Peters; Benjamin A Lipsky
Journal:  Diabetes Care       Date:  2007-02       Impact factor: 19.112

6.  Risk factors for foot infections in individuals with diabetes.

Authors:  Lawrence A Lavery; David G Armstrong; Robert P Wunderlich; M Jane Mohler; Christopher S Wendel; Benjamin A Lipsky
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

7.  Clinical characteristics and outcome in 223 diabetic patients with deep foot infections.

Authors:  M Eneroth; J Apelqvist; A Stenström
Journal:  Foot Ankle Int       Date:  1997-11       Impact factor: 2.827

8.  Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System.

Authors:  Gerald Steinbach; Bettina Rau; Anne-Lise Debard; Jean-François Javourez; Jacques Bienvenu; Antonio Ponzio; Andrea Bonfà; Walter Hubl; Thomas Demant; W R Külpmann; Jana Buchholz; Gerhard Schumann
Journal:  Clin Chem Lab Med       Date:  2004-04       Impact factor: 3.694

Review 9.  Preventive foot care in people with diabetes.

Authors:  J A Mayfield; G E Reiber; L J Sanders; D Janisse; L M Pogach
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112

Review 10.  Diagnosing and treating diabetic foot infections.

Authors:  Benjamin A Lipsky; Anthony R Berendt; John Embil; Fausto De Lalla
Journal:  Diabetes Metab Res Rev       Date:  2004 May-Jun       Impact factor: 4.876

View more
  31 in total

1.  One small step for diabetic podopathy.

Authors:  W Jeffcoate
Journal:  Diabetologia       Date:  2008-02       Impact factor: 10.122

2.  The rapidly expanding role of procalcitonin as a diagnostic and prognostic assay besides in UTIs.

Authors:  Shailendra Kapoor
Journal:  Int Urol Nephrol       Date:  2009-01-08       Impact factor: 2.370

Review 3.  Inflammation: therapeutic targets for diabetic neuropathy.

Authors:  Jiyin Zhou; Shiwen Zhou
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

4.  The role of procalcitonin as a marker of diabetic foot ulcer infection.

Authors:  Mafalda Massara; Giovanni De Caridi; Raffaele Serra; David Barillà; Andrea Cutrupi; Alberto Volpe; Francesco Cutrupi; Antonino Alberti; Pietro Volpe
Journal:  Int Wound J       Date:  2015-10-28       Impact factor: 3.315

Review 5.  Diabetic Foot Infections: Update on Management.

Authors:  Maria Nikoloudi; Ioanna Eleftheriadou; Anastasios Tentolouris; Ourania A Kosta; Nikolaos Tentolouris
Journal:  Curr Infect Dis Rep       Date:  2018-08-01       Impact factor: 3.725

Review 6.  MRSA and diabetic foot wounds: contaminating or infecting organisms?

Authors:  Frank L Bowling; Edward B Jude; Andrew J M Boulton
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

7.  Erythrocyte sedimentation rate and C-reactive protein to monitor treatment outcomes in diabetic foot osteomyelitis.

Authors:  Suzanne Av van Asten; Daniel C Jupiter; Moez Mithani; Javier La Fontaine; Kathryn E Davis; Lawrence A Lavery
Journal:  Int Wound J       Date:  2016-03-08       Impact factor: 3.315

8.  Serum Procalcitonin Concentration and Its Relationship with Local Manifestations after Snakebites.

Authors:  Chanaveerappa Bammigatti; Preetham A Reddy; Nandeesha Hanumanthappa; K T Harichandrakumar; Rathinam Palamalai Swaminathan
Journal:  Am J Trop Med Hyg       Date:  2019-01       Impact factor: 2.345

9.  Risk factors of treatment failure in diabetic foot ulcer patients.

Authors:  Kyung Mook Lee; Woon Hoe Kim; Jang Hyun Lee; Matthew Seung Suk Choi
Journal:  Arch Plast Surg       Date:  2013-03-11

10.  Immune mediators in patients with acute diabetic foot syndrome.

Authors:  Christian Weigelt; Bettina Rose; Ulrike Poschen; Dan Ziegler; Gerd Friese; Kerstin Kempf; Wolfgang Koenig; Stephan Martin; Christian Herder
Journal:  Diabetes Care       Date:  2009-06-09       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.